Pharmazz

Executive Summary

Pharmazz, Inc. is a biopharmaceutical company pioneering first-in-class endothelin-based therapeutics for critical care indications with high unmet medical need. The company’s lead programs target acute cerebral ischemic stroke (Sovateltide) and hypovolemic shock (Centhaquine), both of which are life-threatening conditions with limited treatment options. Sovateltide is a selective endothelin B receptor agonist that promotes neurovascular repair, while Centhaquine acts as a vasopressor via endothelin A receptor antagonism. Both drugs are currently in Phase 3 clinical development, supported by a robust preclinical and early clinical data package suggesting meaningful improvements in survival and functional outcomes. Founded in 2020 and headquartered in Willowbrook, USA, Pharmazz has raised approximately $25 million to advance its pipeline and is positioned as a potential late-stage player in the critical care space. The company’s differentiated mechanism of action and focus on acute hospital settings could offer significant commercial upside if approved.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 3 Results for Sovateltide in Acute Ischemic Stroke70% success
• H1 2027Initiation of Phase 3 Trial for Centhaquine in Hypovolemic Shock60% success
• 2027Strategic Partnership or Licensing Deal for Commercialization50% success